Patient is always in the center of Sanofi’s business. We recognize that meeting our ambitious goal is not something we can accomplish alone. We rely on the cooperation, whose know-how and abilities complement our own. With the cooperation with strong partners, we are full capable to meet patients’ need around the world and in China.
On January 14 2014, Sanofi signed a Memorandum of Understanding on the cooperation with Medical Services Standard Specialized Committee of NHFPC, National Institute of Hospital Administration and Chinese Medical Doctor Association to establish long-term strategic partnerships in the Basic Medical Standard Enhancement Project.
Through this project, Sanofi is able to go out from those big cities, going to counties, going to more patients, bring our know-how with physicians through proper training and the latest training materials – especially in the cardiovascular and diabetes areas, the areas where Sanofi has already built up strong foundation and knowledge, where Sanofi can make a real difference and have the most impact.
In 2014, the BASE project is going to cover 25 provinces, establish 300 additional bases and cover more than 20,000 county physicians.
In additional to partnership, Sanofi is also putting innovation into a key position, going beyond the labs, serving patients’ needs with the right offering.
In April 2014, Sanofi partnered with CMDA to launch the Basal Insulin Standardization Program (COMPLIANCE program) to establish a close loop of patient, doctor and nurse for diabetes management, leverage telecommunication technology properly to facilitate integrated care for diabetes patients, improves the medication compliance of outpatients
Through this project, patients’ fasting plasma glucose data are sent to nurses by SMS or telephone. Nurses record patients’ data into a PAD system and set reminders and patients’ follow-up. Doctors can then read through the PAD system the basal plan information and provide the relevant consultation to patients.
In 2014, the COMPLIANCE program plans to launch in 400 hospitals in 30 provinces, covering more than 1,500 health professional and benefit more than 140,000 diabetes patients.
Sanofi is a global healthcare leader which discovers, develops and distributes therapeutic solutions. Focused on patients' needs, Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Sanofi has a strong commitment to China. In early 1980s, Sanofi became one of the first foreign pharmaceutical companies to open offices in China. Today, Sanofi has 8,500 employees in China, and is one of fastest growing healthcare companies in the country. Sanofi's China headquarters are in Shanghai, supported by 11 regional offices in Beijing, Tianjin, Shenyang, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Jinan and Urumqi.